ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 105 filers reported holding ALBIREO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $274,577 | -52.1% | 12,706 | -57.0% | 0.00% | – |
| Q3 2022 | $573,000 | -62.4% | 29,575 | -61.4% | 0.00% | – |
| Q2 2022 | $1,523,000 | +17.8% | 76,689 | +77.0% | 0.00% | – |
| Q1 2022 | $1,293,000 | -67.6% | 43,327 | -74.7% | 0.00% | -100.0% |
| Q4 2021 | $3,994,000 | -17.7% | 171,467 | +10.3% | 0.00% | 0.0% |
| Q3 2021 | $4,852,000 | +4.1% | 155,517 | +17.4% | 0.00% | 0.0% |
| Q2 2021 | $4,662,000 | -41.1% | 132,508 | -41.0% | 0.00% | -50.0% |
| Q1 2021 | $7,915,000 | -3.3% | 224,546 | +2.9% | 0.00% | 0.0% |
| Q4 2020 | $8,182,000 | +455.1% | 218,137 | +394.0% | 0.00% | – |
| Q3 2020 | $1,474,000 | +196.6% | 44,160 | +135.5% | 0.00% | – |
| Q2 2020 | $497,000 | +128.0% | 18,753 | +40.6% | 0.00% | – |
| Q1 2020 | $218,000 | -14.8% | 13,340 | +32.5% | 0.00% | – |
| Q4 2019 | $256,000 | -57.4% | 10,068 | -66.5% | 0.00% | – |
| Q3 2019 | $601,000 | +180.8% | 30,061 | +398.9% | 0.00% | – |
| Q2 2018 | $214,000 | -87.4% | 6,025 | -88.4% | 0.00% | – |
| Q1 2018 | $1,697,000 | – | 52,107 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |